The company shared its updates at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Amsterdam. It also revealed new findings about attitudes toward the use of technology in the type 2 diabetes population.
Today, the San Diego-based CGM maker announced that its G7 sensor directly connects with the NovoPen 6 and NovoPen Echo Plus in Germany. Novo Nordisk offers these smart, connected insulin pens. Dexcom plans to bring this integration to more markets in the future, too.
According to Dexcom, integrating CGM data with the insulin pen data in one app offers a comprehensive, actionable view of glucose and insulin patterns. This adds to other insulin delivery integrations around the world, as Insulet expanded the availability of its Omnipod 5. The Omnipod 5 integrates with multiple CGMs, including Dexcom’s G6 and G7.
Dexcom also plans to share new data for its 15-day G7 CGM at ATTD, highlighting its accuracy. The company said the 15-day CGM delivered a mean absolute relative difference (MARD) of 8%. It says this improves upon the existing 10-day G7’s accuracy and will be the company’s most accurate CGM offering.
The company submitted its 15-day G7 CGM to the FDA in October 2024. Currently under FDA review, the company says its 15-day G7 also meets integrated CGM (iCGM) standards from the FDA, meaning it would work with compatible insulin delivery systems.
